MedTrace Logo

Adapting LFI for Melioidosis

NCT03528265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-08-01

No results posted yet for this study

Summary

Towards the goal of reducing melioidosis, this study will help clinicians in Sarawak to diagnose and understand the causes and risk factors for melioidosis. The data will help the clinicians to provide faster test results and better clinical care. The investigator's laboratory efforts will supplement available diagnostics by adding a new, easier-to-use test involving lateral flow immunoassay to rapidly detect Burkholderia pseudomallei, a bacterium causing melioidosis. The study aims to study up to 400 patients with melioidosis-like symptoms who are admitted to Kapit Hospital, Sarawak, Malaysia. No participants will be enrolled from other sites. The study will also examine the demographic, behavioral and occupational risk factors associated with hospital admissions to understand any existing associations between these variables and melioidosis prevalence.

Conditions

  • Melioidosis

Interventions

DEVICE

Lateral flow immunoassay

Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis

Sponsors & Collaborators

Principal Investigators

  • Gregory C Gray, MD, MPH · Duke University

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2019-01-08
Completion
2019-01-08
FDA Device
Yes

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03528265 on ClinicalTrials.gov